NIH Biodefense "Partnerships" Bioweaponeering News on Stealth Disablers, ie., Borreliosis (Lyme):

1)  "Accordingly, the methods of the invention provide a powerful and selective approach for modulating the innate immune response pathways in animals without giving rise to the toxicities often associated with the native bacterial components that normally stimulate those pathways."   http://patft.uspto.gov/6,800,613

 

Dave, ya think?   (Yale, et al deliberately did not report adverse events to OspA/LYMErix to the FDA)

 

2) US Bioweaponeers   =  How Lyme disease and LYMErix cause immune-suppression related illnesses- tolerization to the antigens.  This is why Lyme and Syphilis are "steath pathogens."  (Go to PubMed and enter "Radolf JD and stealth pathogen" without the quotes)

 

3) "Although a single ligation of TLRs induces responses such as TNF production, repeated ligation will lead to a loss of response, i.e., the cells become tolerant."   http://www.jimmunol.org/cgi/content/full/173/4/2736

 

4) "Borrelia burgdorferi-Induced Tolerance as a Model of Persistence via Immunosuppression" -  "In summary, we characterized tolerance induced by B. burgdorferi, describing a model of desensitization which might mirror the immunosuppression recently attributed to the persistence of Borrelia in immunocompetent hosts." HERE

 

Lemme think.  Could chronic Lyme being "seronegative," as described above, have anything to do with borreliosis being "the perfect stealth pathogen," as the Department of Defense says?

 

(Hilarious)

"Explains Barbour: "It's like a bacterial Star Wars defense program," in which released surface proteins might intercept incoming host antibodies, keeping the spirochete safe from immunological attack. "

 

It's more like "the blebbing is like flak" and it means this leads to tolerization, that there can never be a vaccine for Lyme, and that the only antibody test that is accurate is Borreliae-specific flagellins.

 

FROM BARBOUR's FLAGELLA-LESS SPIROCHETE PATENT (below)

Note that no one can have an antibody to flagellin (band 41)  and be sick, yet antibodies to flagellin being toxic is the reason there is no flagellar vaccine for Lyme.  Let me say that more clearly:  No one who has band 41 is allowed to either have Lyme disease or be sick, yet because band 41 is associated with how Lyme makes us sick is the reason we can't have a Lyme vaccine based on flagellin. 

Make sense? 

No.  But then again, the Infectious Diseases Society of America says Lyme is not either fatal or chronic, while at the same time they themselves have published that Lyme is associated with about 1/2 the Lou Gehrig's Diseases cases. 

Make sense?

No. 

So what's the answer?

Say it in unison, folks:

"GIVE  THE  LYING  LYME  CROOKS  MORE  GRANT MONEY  TO  PUBLISH  MORE  BOGUS  ARTICLES,  AND TRY  TO  SELL  MORE  BOGUS  VACCINES  FOR DISEASES THAT  THEY  ALSO  CLAIM  DO  NOT  EXIST!!!"

http://patft.uspto.gov/5,585,102

"Although several investigators have suggested use of an immunoassay using a purified flagella protein antigen, there are problems with this approach. For one thing, it has recently been shown that a monoclonal antibody directed against the major flagella protein of Borrelia burgdorferi also recognizes human tissue, including myelin and Schwann cells from the peripheral nervous system (Sigal, et al., 1988; Aberer, et al., 1989). Autoantibodies against neural antigens have been observed in the serum of patients with Lyme disease. These findings suggest that autoreactive antibodies may complicate interpretation of immunoassays that use purified flagellar antigen or whole cell sonicates containing flagella antigen. Another problem with the use of preparations containing the flagellum by itself or in combination with other components is that there may be false positive reactions as a consequence of antigenic similarities between the flagella of borreliae and the flagella of other bacteria.

"The discovery that flagellar antigens may induce formation of antibodies reactive with human neural tissue provides an additional problem with respect to development of a vaccine against Lyme Disease. International Patent Application No. WO 90/04411, published May 3, 1990 describes a method for preparing fractions of Borrelia burgdorferi in which the flagellar components are at least partially depleted. However, that method is somewhat time consuming and labor intensive. Inactivated whole cell Borrelia burgdorferi vaccines, such as those described in U.S. Pat. No. 4,721,617 and by Johnson, et al., 1986, comprise a relatively high proportion of the flagellar antigen and may thus induce an undesirable auto immune response. In addition, because flagellated Borrelia is virulent, the cells must be killed prior to administration, thus reducing immunogenicity. Because the flagellum is an important virulence factor of the organism, development of a flagellar-less strain could provide an ideal approach for development of an attenuated vaccine. .."